UNIGE document Scientific Article
previous document  unige:32220  next document
add to browser collection
Title

Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression

Authors
Jaquenoud Sirot, Eveline
Harenberg, Sabine
Vandel, Pierre
Lima, Carlos A Mendonça
Perrenoud, Patrick
Kemmerling, Klaus
show hidden authors show all authors [1 - 14]
Published in Journal of Clinical Psychopharmacology. 2012, vol. 32, no. 5, p. 622-9
Abstract Pharmacogenetic tests and therapeutic drug monitoring may considerably improve the pharmacotherapy of depression. The aim of this study was to evaluate the relationship between the efficacy of mirtazapine (MIR) and the steady-state plasma concentrations of its enantiomers and metabolites in moderately to severely depressed patients, taking their pharmacogenetic status into account. Inpatients and outpatients (n = 45; mean age, 51 years; range, 19-79 years) with major depressive episode received MIR for 8 weeks (30 mg/d on days 1-14 and 30-45 mg/d on days 15-56). Mirtazapine treatment resulted in a significant improvement in mean Hamilton Depression Rating Scale total score at the end of the study (P < 0.0001). There was no evidence for a significant plasma concentration-clinical effectiveness relationship regarding any pharmacokinetic parameter. The enantiomers of MIR and its hydroxylated (OH-MIR) and demethylated (DMIR) metabolites in plasma samples on days 14 and 56 were influenced by sex and age. Nonsmokers (n = 28) had higher mean MIR plasma levels than smokers (n = 17): S(+)-enantiomer of MIR, 9.4 (SD, 3.9) versus 6.2 (SD, 5.5) ng/mL (P = 0.005); R(-)-enantiomer of MIR, 24.4 (SD, 6.5) versus 18.5 (SD, 4.1) ng/mL (P = 0.003). Only in nonsmokers, plasma levels of S(+)-enantiomer of MIR and metabolites depended on the CYP2D6 genotype. Therefore, high CYP1A2 activity seen in smokers seems to mask the influence of the CYP2D6 genotype. In patients presenting the CYP2B6 *6/*6 genotype (n = 8), S-OH-MIR concentrations were higher those in the other patients (n = 37). Although it is not known if S-OH-MIR is associated with the therapeutic effect of MIR, the reduction of the Hamilton scores was significantly (P = 0.016) more pronounced in the CYP2B6 *6/*6-genotyped patients at the end of the study. The role of CYP2B6 in the metabolism and effectiveness of MIR should be further investigated.
Keywords AdultAge FactorsAgedAntidepressive Agents, Tricyclic/chemistry/pharmacokinetics/therapeutic useCytochrome P-450 CYP1A2/metabolismCytochrome P-450 CYP2D6/geneticsDepressive Disorder, Major/drug therapy/physiopathologyDrug Monitoring/methodsFemaleGenotypeHumansMaleMianserin/analogs & derivatives/chemistry/pharmacokinetics/therapeutic useMiddle AgedPharmacogeneticsPsychiatric Status Rating ScalesSex FactorsSmoking/metabolismStereoisomerismTreatment OutcomeYoung Adult
Identifiers
PMID: 22926595
Full text
Article (Published version) (197 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research group Abus de substances (834)
Citation
(ISO format)
JAQUENOUD SIROT, Eveline et al. Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression. In: Journal of Clinical Psychopharmacology, 2012, vol. 32, n° 5, p. 622-9. https://archive-ouverte.unige.ch/unige:32220

171 hits

0 download

Update

Deposited on : 2013-12-16

Export document
Format :
Citation style :